There are 2789 resources available
1352P - A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy
Presenter: Giulia Mazzaschi
Session: ePoster Display
1353P - Similarities and differences in the spatial distribution of brain metastases in small cell lung cancer and non-small cell lung cancer: Quantitative analysis and identifying metastatic risk region may be helpful for the whole-brain radiotherapy with non-uniform dose prescriptions
Presenter: Rongjie Tao
Session: ePoster Display
Resources:
Abstract
1243P - Cumulative incidence and metastatic patterns of relapsed vs de novo stage IV non-small cell lung cancer (NSCLC) characterized by histology and EGFR status
Presenter: Evan Strom
Session: ePoster Display
1244P - Real-world EGFR and T790M testing patterns in patients from Central Eastern Europe with advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)
Presenter: Mircea Dediu
Session: ePoster Display
1196P - Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: ePoster Display
1197P - First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN
Presenter: Qing Zhou
Session: ePoster Display
1198P - Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
Presenter: Claudia Parisi
Session: ePoster Display
1199P - Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: ePoster Display
1201P - Real-world comparative effectiveness of 1L alectinib (ALC) vs crizotinib (CRZ) in patients (pts) with ALK+ advanced NSCLC with or without baseline CNS metastases (mets)
Presenter: Matthew Krebs
Session: ePoster Display